What Lilly and Viking's GLP-1 race means for your vials

Wall Street is currently arguing about which company will win the next round of GLP-1 drug development: Eli Lilly or Viking Therapeutics. That's a stock story. But underneath it is a real chemistry story, and it matters to anyone who reconstitutes these peptide classes at the bench. The short version: the industry is moving from single-target peptides to peptides that hit two or three receptors at once. That shift changes what you're actually holding in the vial.

From one target to three

GLP-1 (glucagon-like peptide-1) is a small hormone your gut makes naturally. It locks onto GLP-1 receptors, which sit on cells in the pancreas, brain, and gut, and triggers a chain of downstream effects. The first wave of GLP-1 research peptides, like semaglutide, only hit that one receptor.

Eli Lilly's tirzepatide (sold as Mounjaro and Zepbound) was the first approved peptide to hit two receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone with its own receptor. Lilly has since moved further with retatrutide, a peptide built to hit three receptors: GLP-1, GIP, and glucagon. Viking Therapeutics' lead candidate, VK2735, is also a dual GLP-1/GIP agonist, developed in both an injectable and an oral pill form, and it's the compound investors are watching as Viking's answer to Lilly's pipeline.

Here's the part that matters for research purposes: adding receptor targets means adding amino acids and structural complexity to the peptide backbone. A dual or triple agonist isn't just "a stronger GLP-1 peptide." It's a chemically different, usually larger molecule, engineered to bind more than one receptor shape at once.

Why bigger, multi-target peptides need more care

Every added amino acid is another place a peptide can degrade: through oxidation, where oxygen reacts with sensitive side chains, or deamidation, where certain residues slowly convert to a different form over time. Bigger, multi-target peptides simply have more of these vulnerable spots. That's not a reason to panic. It's a reason to be stricter about the basics: reconstitute with clean bacteriostatic water, not tap or plain sterile water, and get vials into cold, dark storage right after mixing instead of leaving them on the bench.

Your reconstitution math changes too

Dual and triple agonist peptides typically have a higher molecular weight than single-target GLP-1 peptides. That matters if you're converting between milligrams and molar concentration, because molecular weight is part of that calculation. A reconstitution worksheet built around a smaller single-target peptide won't give you the right molar concentration if you plug in numbers for a larger dual or triple agonist without adjusting for its actual weight. Always check the certificate of analysis or vendor spec sheet for the specific molecule's molecular weight before you do the math, rather than assuming it matches a peptide you've used before.

What the research community gets wrong about these peptides

• Assuming "dual" or "triple" automatically means a more stable molecule. More receptor targets usually means more structural complexity, not less, so these peptides deserve the same or greater care in storage and handling as simpler ones.
• Treating pharma approval news as a purity signal. A company's clinical trial progress or FDA status says nothing about the purity or handling of a specific vial in your freezer. Only your vendor's certificate of analysis does that.
• Reusing an old reconstitution spreadsheet without updating the molecular weight. Dual and triple agonists are heavier molecules than single-target GLP-1 peptides; skipping this step throws off your concentration math.
• Assuming "GLP-1/GIP dual agonist" on a label always means the identical clinical-grade sequence. Naming conventions in the research supply space aren't standardized, so always confirm the actual sequence and source, not just the marketing name.
• Leaving reconstituted multi-target peptides at room temperature "just for a bit." The added oxidation-prone sites in larger peptides make brief warm exposure a bigger risk to the sample than it would be for a shorter single-target chain.

Frequently asked questions

What is the difference between a GLP-1 agonist and a dual GLP-1/GIP agonist?

A single agonist binds only the GLP-1 receptor. A dual agonist, like tirzepatide-type peptides, is engineered to also bind the GIP receptor, requiring a larger and more complex amino acid chain.

Does a bigger peptide molecule degrade faster in storage?

Not automatically, but more amino acids means more potential oxidation and deamidation sites, so multi-target peptides generally warrant stricter cold, dark storage after reconstitution.

Why does molecular weight matter for peptide reconstitution math?

Molecular weight is part of converting between milligrams and molar concentration. Dual and triple agonist peptides are heavier than single-target ones, so using the wrong weight skews your concentration calculations.

Prompted by this coverage at Google News →

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.